I-Mab Biopharma US Limited
Clinical trials sponsored by I-Mab Biopharma US Limited, explained in plain language.
I-Mab Biopharma US Limited
IMAB
NASDAQ
A biopharmaceutical company developing immunotherapies.
Not investment advice. Company information is shown for context only. Clinical trials frequently fail.
Advertising disclosure. Links marked "(ad)" go to partners we have a commercial relationship with, either a broker where you can trade or a stock-research service, and we may earn a commission if you open an account or subscribe. This never affects what is shown here.
Upcoming readouts
Trials from this sponsor expected to report results within the next 12 months.
- New hope for Hard-to-Treat cancers: experimental drug enters human trials Results expected Dec 2026 (estimated)